|

Multicenter Study for External Validation of the TB-NET Score

RECRUITINGSponsored by Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Actively Recruiting
SponsorInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Started2026-05-12
Est. completion2027-03
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations2 sites

Summary

This is a retrospective, observational, multicenter study aiming to externally validate the TB-NET Score in an independent cohort of patients with advanced well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) or lung carcinoids. The primary objective is to validate the prognostic value of the TB-NET Score for progression-free survival (PFS). Secondary objectives include the evaluation of overall survival (OS), objective response rate (ORR), grade 3-4 adverse events, biochemical and functional imaging correlates, and the potential additional prognostic value of tumor growth rate (TGR).

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Adult patients with histologically confirmed well differentiated advanced GEP-NETs or Lung Carcinoids starting any line of systemic therapy.
* Grade 1, 2 or 3 if well-differentiated morphology for GEP-NETs. Typical or Atypical Lung Carcinoids.
* At least one target lesion.

Exclusion Criteria:

* Patients with Neuroendocrine Carcinomas.
* Patients with no target lesions (according to RECIST 1.1 criteria).

Conditions3

CancerNeuroendocrine (NE) TumorsTumor Burden

Locations2 sites

Massachusetts

1 site
Dana-Farber Cancer Institute
Jennifer Chan, MD617-632-3000jennifer_chan@dfci.harvard.edu

Missouri

1 site
Mallinckrodt Institute of Radiology
St Louis, Missouri, 63110
Prasad Vikas, MD314-362-1474pvikas@wustl.edu

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.